Jason Barrett
Psychiatry · Los Angeles, CANPI 1023549102
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 216 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Johnson & Johnson at 27.0% of the total. 2025 is the largest year on record at $3,295, 6.0 times the $553 reported in 2022. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $38.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$857
- Alkermes, Inc.$804
- Neurocrine Biosciences, Inc.$768
- Teva Pharmaceuticals USA, Inc.$733
- plus $2K from 9 others
What the payments were for
- Food & beverage$8,23899%
- Education$1111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 51 | $2,251 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $1,123 |
| AbbVie | 25 | $857 |
| Alkermes, Inc. | 17 | $804 |
| Neurocrine Biosciences, Inc. | 36 | $768 |
| Teva Pharmaceuticals USA, Inc. | 23 | $733 |
| Otsuka America Pharmaceutical, Inc. | 16 | $641 |
| E.r. Squibb & Sons, L.L.C. | 13 | $630 |
| Vanda Pharmaceuticals Inc. | 5 | $210 |
| Ironshore Pharmaceuticals Inc. | 3 | $138 |
| Bioxcel Therapeutics, Inc. | 1 | $78 |
| Lundbeck LLC | 1 | $34 |
| Harmony Biosciences LLC | 1 | $31 |
| Indivior Inc. | 1 | $28 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$1,329
- LYBALVI$987
- ARISTADA$879
- INVEGA TRINZA$779
- CAPLYTA$769
- COBENFY$375
- VRAYLAR$362
- ABILIFY MAINTENA$244
- ABILIFY ASIMTUFII$244
- ARISTADA INITIO$220
- REXULTI$219
- Fanapt$125
- INGREZZA$123
- AUSTEDO$121
- UZEDY$121
- JORNAY PM$110
How this compares
$8,349 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 13 | $1,400 |
| Aripiprazole | 19 | $982 |
| Duloxetine Hcl | 20 | $105 |
| Trazodone Hcl | 18 | $99 |
| Quetiapine Fumarate | 19 | $67 |
| Clonazepam | 12 | $8 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Los Angeles
- Jakub JurosLos Angeles$394K
- Derek OttLos Angeles$329K
- William WirshingLos Angeles$205K
- Gil HoftmanLos Angeles$200K
- Lon SchneiderLos Angeles$156K
- Stephen MarderLos Angeles$103K
- John BrooksLos Angeles$80K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.